LEADING MED
SUPPLEMENTS
LEADING MED
SUPPLEMENTS
LEADING MED
SUPPLEMENTS
Overcoming the limitations of traditional supplements
LeadingMed supplements are the result of scientific innovation and experience in the nutraceutical sector, with the aim of offering more effective solutions with high bioavailability. Thanks to the patented FM-LipoMatrix® technology, we have overcome the limitations of traditional supplements, improving the absorption and effectiveness of the active ingredients.
Our research is based on rigorous quality standards and collaboration with universities and scientific partners of excellence. Each formulation is designed to ensure maximum safety, high stability and concrete results, offering targeted support for daily well-being and the treatment of specific physiological needs.
Linea FM-LipoMatrix® e PEA
Linea Reviscon e Vis
Overcoming the limitations of traditional supplements
LeadingMed supplements are the result of scientific innovation and experience in the nutraceutical sector, with the aim of offering more effective solutions with high bioavailability. Thanks to the patented FM-LipoMatrix® technology, we have overcome the limitations of traditional supplements, improving the absorption and effectiveness of the active ingredients.
Our research is based on rigorous quality standards and collaboration with universities and scientific partners of excellence. Each formulation is designed to ensure maximum safety, high stability and concrete results, offering targeted support for daily well-being and the treatment of specific physiological needs.
Linea Norm
Liena FM-LipoMatrix® e PEA
Linea Reviscon e Vis
LEADING MED
FM-LipoMatix®
Supplements are food substitutes composed of inorganic substances: a combination of laboratory-synthesised nutrients put together in a formulation that ends up in the “cupboards” of doctors and patients. But our bodies are designed to naturally assimilate organic substances, not laboratory-synthesised extracts, which is essentially what all supplements are made of.
This creates a rather logical short circuit: it concerns the major limitation of absorption of supplements, which are not recognised by the body as organic and tend to largely fail in their therapeutic mission.
This is where LeadingMed comes in: scientific research has led to the development of a new advanced technology, FM-LipoMatrix®, which enhances the properties and capabilities of the liposomal matrix in order to increase the bioavailability and absorption of our supplements.
FM-LipoMatrix®, the result of joint efforts by LeadingMed and partners of excellence such as Pro-Bio Pharma, has led to the creation of a high-quality product, the result of a patent (No. 102017000036744) developed in collaboration with the universities of Bologna, Pavia and Eastern Piedmont.
Together, we have managed to overcome the limitations of nutraceuticals of the past and present, achieving absorption levels ranging from 50% to 300% higher than other similar supplements on the market.
LEADING MED
FM-LipoMatix®
We manage the distribution of medicines using an advanced logistics system, ensuring fast delivery times, safety and compliance with current regulations.
Our network and technologies allow us to optimise the entire process, ensuring maximum efficiency in the supply of essential products for the healthcare sector.
NORM LINE
The Nutraceutical revolution thanks to FM-LipoMatrix® technology.
All Norm Line products are made with the finest raw materials that undergo numerous microbiological tests, both in vivo and in vitro, in terms of both safety and stability, confirming the total absence of pesticides, radioactive waste and chemicals. Production takes place in clean rooms with constantly filtered air to prevent contamination, while temperature and humidity are closely monitored to ensure impeccable quality.
The production process follows the most rigorous GMP (Good Manufacturing Practices) standards for food supplements, as established by the World Health Organisation (WHO).
The Norm Line is the result of a revolutionary, patented technology that we have named FM-LipoMatrix®.
It is a blend of vegetable oils complexed with specific components, with its own biological activity, capable of improving the effectiveness of lipophilic substances in nutraceutical (and pharmaceutical) formulations.
But that’s not all. FM-LipoMatrix® also allows for:
– greater water solubility of fat-soluble substances and superior stability of active components;
– optimisation of intestinal absorption and increased bioavailability of ingredients, from 50 to 300%, thanks to an improved delivery system;
– a drastic reduction in side effects due to high dosages
All active ingredients are initially subjected to the fluidisation process: a bed of particles in the product container is transformed into a fluid state by an upward flow of liquid or gas. When the bed is completely fluidised, the granulation liquid is then added: FM-LipoMatrix® technology.
A New Palmitoylethanolamide Form Combined with Antioxidant Molecules to Improve Its Effectivess on Neuronal Aging
Vera Morsanuto *, Rebecca Galla, Claudio Molinari † and Francesca Uberti *,† Laboratory of Physiology, Department of Translational Medicine, University of Piemonte Orientale, Italy
8 May 2020; Accepted: 9 July 2020; Published: 17 July 2020
NORM LINE
The Nutraceutical revolution thanks to FM-LipoMatrix® technology.
All Norm Line products are made with the finest raw materials that undergo numerous microbiological tests, both in vivo and in vitro, in terms of both safety and stability, confirming the total absence of pesticides, radioactive waste and chemicals. Production takes place in clean rooms with constantly filtered air to prevent contamination, while temperature and humidity are closely monitored to ensure impeccable quality.
The production process follows the most rigorous GMP (Good Manufacturing Practices) standards for food supplements, as established by the World Health Organisation (WHO).
The Norm Line is the result of a revolutionary, patented technology that we have named FM-LipoMatrix®.
It is a blend of vegetable oils complexed with specific components, endowed with its own biological activity, capable of improving the effectiveness of lipophilic substances in nutraceutical (and pharmaceutical) formulations.
But that’s not all. FM-LipoMatrix® also allows for:
– greater water solubility of fat-soluble substances and superior stability of active components;
– optimisation of intestinal absorption and increased bioavailability of ingredients, from 50 to 300%, thanks to an improved delivery system;
– a drastic reduction in side effects due to high dosages.
All active ingredients are initially subjected to the fluidisation process: a bed of particles in the product container is transformed into a fluid state by an upward flow of liquid or gas. When the bed is completely fluidised, the granulation liquid is added: FM-LipoMatrix® technology.
A New Palmitoylethanolamide Form Combined with Antioxidant Molecules to Improve Its Effectivess on Neuronal Aging
Vera Morsanuto *, Rebecca Galla, Claudio Molinari † and Francesca Uberti *,† Laboratory of Physiology, Department of Translational Medicine, University of Piemonte Orientale, Italy
8 May 2020; Accepted: 9 July 2020; Published: 17 July 2020
FM-LIPOMATRIX® AND PEA LINE
Palmitoylethanolamide, or PEA, is a long-chain carbon atom molecule that combines with palmitic acid and an ethanolamine group.
It is a molecule with extremely interesting active ingredients in cases of chronic or acute pain and inflammation: by not binding directly to endocannabinoid receptors but acting as a mediator, palmitoylethanolamide participates in the biological response of endogenous cannabinoids and prevents their degradation, thus prolonging their action against pain.
It is no coincidence that Professor Rita Levi Montalcini was among the most eminent scientific sources to extol the therapeutic value of the PEA molecule in our country: ‘Palmitoylethanolamide is active when taken orally in reducing tissue inflammation and mast cell degranulation in vivo, decreasing the hyperalgesia that accompanies peripheral nerve compression’*.
PEA exhibits significant anti-inflammatory, analgesic, immunomodulatory and neuroprotective effects, allowing the restoration of glutamatergic transmission homeostasis. Furthermore, PEA’s ability to modulate protective responses during inflammation derives from its belonging to the homeostatic system that controls inflammation, which can counteract the release of inflammatory mediators synthesised de novo by activated mast cells.
Numerous studies and ongoing research highlight the potential of this molecule in the anti-inflammatory and analgesic treatment of clinical conditions with different aetiologies. Without side effects.**
The only drawback, in an otherwise exceptional picture, is its poor bioavailability.
This is where FM-LipoMatrix® comes into play: this is where Artonorm and Peanorm products are born.
* Levi-Montalcini R; Trends Neurosci. 1996 Nov;19(11):514-20. Review
** Review: The Basal Pharmacology of Palmitoylethanolamide
Linda Rankin † and Christopher J. Fowler * Department of Integrative Medical Biology, Umeå University, SE-901 87 Umeå, Sweden;
Published: 26 October 2020
FM-LIPOMATRIX® LINE
AND PEA
Palmitoylethanolamide, or PEA, is a long-chain carbon atom molecule that combines with palmitic acid and an ethanolamine group.
It is a molecule with extremely interesting active ingredients in cases of chronic or acute pain and inflammation: by not binding directly to endocannabinoid receptors but acting as a mediator, palmitoylethanolamide participates in the biological response of endogenous cannabinoids and prevents their degradation, thus prolonging their action against pain.
It is no coincidence that Professor Rita Levi Montalcini was among the most eminent scientific sources in Italy to extol the therapeutic value of the PEA molecule: ‘Palmitoylethanolamide is active when taken orally in reducing tissue inflammation and mast cell degranulation in vivo, decreasing the hyperalgesia that accompanies peripheral nerve compression’*.
PEA exhibits significant anti-inflammatory, analgesic, immunomodulatory and neuroprotective effects, allowing the restoration of glutamatergic transmission homeostasis. Furthermore, PEA’s ability to modulate protective responses during inflammation derives from its belonging to the homeostatic system that controls inflammation, which can counteract the release of inflammatory mediators synthesised de novo by activated mast cells.
Numerous studies and ongoing research highlight the potential of this molecule in the anti-inflammatory and analgesic treatment of clinical conditions with different aetiologies. Without side effects.**
The only drawback, in an otherwise exceptional picture, is its poor bioavailability.
This is where FM-LipoMatrix® comes into play: this is where Artonorm and Peanorm products are born.
* Levi-Montalcini R; Trends Neurosci. 1996 Nov;19(11):514-20. Review
** Review: The Basal Pharmacology of Palmitoylethanolamide
Linda Rankin † and Christopher J. Fowler * Department of Integrative Medical Biology, Umeå University, SE-901 87 Umeå, Sweden;
Published: 26 October 2020
REVISCON LINE AND VIS LINE
The innovation of hyaluronic acid for joint health
Hyaluronic acid plays a fundamental role in the health and stability of the joint environment: the positive response to the stresses required by movement and natural load variations depends largely on its presence in terms of quantity and quality. In individuals with osteoarthritis, for example, the molecular weight and concentration of hyaluronic acid are reduced, leading to cartilage degeneration.
To address this issue, LeadingMed has developed the Reviscon and Vis lines, exploiting the unique viscous and elastic properties of a completely innovative hyaluronic acid, the result of intensive scientific research and sector studies.
– The REVISCON LINE offers a high molecular weight infiltration therapy based on new generation, highly biocompatible hyaluronic acid.
Reviscon is highly purified, high molecular weight sodium hyaluronate dissolved in physiological solution.
All synovial joints naturally contain viscoelastic sodium hyaluronate, especially those that bear weight.
In patients with osteoarthritis, for example, the viscoelasticity of the synovial fluid is rather reduced: this causes mechanical stress on the joint, leading to the breakdown of the articular cartilage and thus limiting mobility and causing considerable pain
Thanks to its range of products, the Reviscon Line relieves pain and contributes to improving overall mobility: in fact, the complex viscosity typical of hyaluronic acid gives it both viscous and elastic properties that are essential for joint health.
The excellent rheological profile of the Reviscon line allows for optimal viscosity at rest (up to 5 times higher than many similar products on the market), and therefore an equally optimal reduction in pain thanks to superior dynamic elasticity when the effort is high.
– Reviscon 20 mg in 2 ml: 3/5 injections for gradual therapy;
– Reviscon Mono 48 mg in 2.4 ml: a single injection, high performance;
– Reviscon Plus 32 mg in 2 ml: high efficacy in 2/3 injections.
The VIS LINE offers an infiltrative therapy based on hyaluronic acid, specialised in reducing symptoms and inflammation, increasing lubrication and viscosity in the joints.
RenehaVis (LMW-HMW dual chamber mix) – 1 to 3 injections per week
RenehaVis consists of a sterile, pre-filled, ready-to-use dual chamber glass syringe containing:
– Chamber 1: Low molecular weight (LMW) sodium hyaluronate 0.7 ml sterile 2.2% sodium hyaluronate Molecular weight 1 x 106 Da.
– Chamber 2: High molecular weight (HMW) sodium hyaluronate 0.7 ml sterile sodium hyaluronate 1.0% molecular weight 2 x 106 Da.
RenehaVis is particularly effective in reducing pain and stiffness in the knee joint in patients with synovial joint degeneration
The high degree of reliability of RenehaVis is due to its physicochemical properties: the LMW and HMW sodium hyaluronate contained in RenhaVis is a biopolymer composed of disaccharide units of N-acetylglucosamine and glucuronic acid obtained through the biosynthesis of Streptococcus equi, identical to the sodium hyaluronate naturally found in synovial joints, but which may have been altered by degenerative or traumatic changes in the synovial joint.
RenehaVis supplements synovial sodium hyaluronate that has undergone changes in molecular weight and concentration.
TendoVis (soft tissue adapted biocompatible Hyaluronic Acid) – 2 injections (one per week)
TendoVis is indicated for periarticular injections for damaged or compromised tendons and ligaments.
– Modulates inflammation
– Reduces pain
– Protects and supports the damaged area
– Reduces the risk of recurrence
– Reduces recovery time
– Facilitates proper realignment of tendons, resulting in recovery of function
TendoVis is a sterile glass syringe containing sodium hyaluronate with a pH and osmolarity that are biocompatible with soft tissues. It is therefore suitable for periarticular injection, specifically into the soft tissues surrounding tendons and ligaments.
TendoVis is indicated for patients with rotator cuff tendinopathy, epicondylitis and ankle sprains: thanks to a sophisticated patented production process (STABHA patent, Soft Tissue Adapted Biocompatible, Hyaluronic Acid), it allows for prolonged retention time and avoids degradative reactions by the body (thanks to the absence of endotoxin and nucleic acids)
*The I.D.E.H.A. Study Intra-articular Double Molecular Weight Efficacy of Hyaluronic Acid
Autori: Dr. Romeo Gatti, Xuming Shen – IDEHA Group
Pazienti: 1.214 pazienti in Italia (Multicentro che ha coinvolto oltre 50 medici) PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24416477
SICUREZZA E EFFICACIA NELLA RIDUZIONE DEL DOLORE
Long term efficacy and safety of a combined low and high molecular weight hyaluronic acid in the treatment of osteoarthritis of the knee
Autori: Robert J. Petrella, Joseph Decaria, Michael Petrella
PubMed: http://www.pagepress.org/journals/index.php/rr/article/view/rr.2011.e4/2729
EULAR ROME 2010
EFFICACIA A LUNGO TERMINE (12-24 MESI) E MAGGIORE EFFICACIA RISPETTO ALLE TERAPIE CONVENZIONALI
Efficacy of DualVis (Renehavis) for Knee Osteoarthritis in Indonesia
Autori: Prof. Handono Kalim, Dr. Arif Sumardjono, Dr. Nyimas Fatimah.
REVISCON LINE
AND VIS LINE
AND VIS LINE
The innovation of hyaluronic acid for joint health
Hyaluronic acid plays a fundamental role in the health and stability of the joint environment: the positive response to the stresses required by movement and natural load variations depends largely on its presence in terms of quantity and quality. In individuals with osteoarthritis, for example, the molecular weight and concentration of hyaluronic acid are reduced, leading to cartilage degeneration.
To address this issue, LeadingMed has developed the Reviscon and Vis lines, exploiting the unique viscous and elastic properties of a completely innovative hyaluronic acid, the result of intensive scientific research and sector studies
– The REVISCON LINE offers a high molecular weight infiltration therapy based on new generation, highly biocompatible hyaluronic acid.
Reviscon is highly purified, high molecular weight sodium hyaluronate dissolved in physiological solution.
All synovial joints naturally contain viscoelastic sodium hyaluronate, especially those that bear weight.
In patients with osteoarthritis, for example, the viscoelasticity of the synovial fluid is rather reduced: this causes mechanical stress on the joint, leading to the breakdown of the articular cartilage and thus limiting mobility and causing considerable pain
Thanks to its range of products, the Reviscon Line relieves pain and contributes to improving overall mobility: in fact, the complex viscosity typical of hyaluronic acid gives it both viscous and elastic properties that are essential for joint health.
The excellent rheological profile of the Reviscon line allows for optimal viscosity at rest (up to 5 times higher than many similar products on the market), and therefore an equally optimal reduction in pain thanks to superior dynamic elasticity when the effort is high.
– Reviscon 20 mg in 2 ml: 3/5 injections for gradual therapy;
– Reviscon Mono 48 mg in 2.4 ml: a single injection, high performance;
The VIS LINE offers an infiltrative therapy based on hyaluronic acid, specialised in reducing symptoms and inflammation, increasing lubrication and viscosity in the joints.
RenehaVis (LMW-HMW dual chamber mix) – 1 to 3 injections per week
RenehaVis consists of a sterile, pre-filled, ready-to-use dual chamber glass syringe containing:
– Chamber 1: Low molecular weight (LMW) sodium hyaluronate 0.7 ml sterile 2.2% sodium hyaluronate Molecular weight 1 x 106 Da.
– Chamber 2: High molecular weight (HMW) sodium hyaluronate 0.7 ml sterile sodium hyaluronate 1.0% molecular weight 2 x 106 Da.
RenehaVis is particularly effective in reducing pain and stiffness in the knee joint in patients with synovial joint degeneration
The high degree of reliability of RenehaVis is due to its physicochemical properties: the LMW and HMW sodium hyaluronate contained in RenhaVis is a biopolymer composed of disaccharide units of N-acetylglucosamine and glucuronic acid obtained through the biosynthesis of Streptococcus equi, identical to the sodium hyaluronate found naturally in synovial joints, but which may have been altered by degenerative or traumatic changes in the synovial joint.
RenehaVis supplements synovial sodium hyaluronate that has undergone changes in molecular weight and concentration
TendoVis (soft tissue adapted biocompatible Hyaluronic Acid) – 2 injections (one per week)
TendoVis is indicated for periarticular injections for damaged or compromised tendons and ligaments.
– Modulates inflammation
– Reduces pain
– Protects and supports the damaged area
– Reduces the risk of recurrence
– Reduces recovery time
– Facilitates proper realignment of tendons, resulting in recovery of function.
TendoVis is a sterile glass syringe containing sodium hyaluronate with a pH and osmolarity that are biocompatible with soft tissues. It is therefore suitable for periarticular injection, specifically into the soft tissues surrounding tendons and ligaments.
TendoVis is indicated for patients with rotator cuff tendinopathy, epicondylitis and ankle sprains: thanks to a sophisticated patented production process (STABHA patent, Soft Tissue Adapted Biocompatible, Hyaluronic Acid), it allows for prolonged retention time and avoids degradative reactions by the body (thanks to the absence of endotoxins and nucleic acids).
*The I.D.E.H.A. Study Intra-articular Double Molecular Weight Efficacy of Hyaluronic Acid
Autori: Dr. Romeo Gatti, Xuming Shen – IDEHA Group
Pazienti: 1.214 pazienti in Italia (Multicentro che ha coinvolto oltre 50 medici) PubMed: http://www.ncbi.nlm.nih.gov/pubmed/24416477
SICUREZZA E EFFICACIA NELLA RIDUZIONE DEL DOLORE
Long term efficacy and safety of a combined low and high molecular weight hyaluronic acid in the treatment of osteoarthritis of the knee
Autori: Robert J. Petrella, Joseph Decaria, Michael Petrella
PubMed: http://www.pagepress.org/journals/index.php/rr/article/view/rr.2011.e4/2729
EULAR ROME 2010
EFFICACIA A LUNGO TERMINE (12-24 MESI) E MAGGIORE EFFICACIA RISPETTO ALLE TERAPIE CONVENZIONALI
Efficacy of DualVis (Renehavis) for Knee Osteoarthritis in Indonesia
Autori: Prof. Handono Kalim, Dr. Arif Sumardjono, Dr. Nyimas Fatimah.
REQUEST INFORMATION
REQUEST INFORMATION